https://wikimd.org/index.php?action=history&feed=atom&title=RisankizumabRisankizumab - Revision history2026-04-30T04:03:56ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=Risankizumab&diff=5343489&oldid=prevPrab: CSV import2024-03-02T15:01:42Z<p>CSV import</p>
<p><b>New page</b></p><div>'''Risankizumab''' is a humanized [[monoclonal antibody]] designed for the treatment of [[psoriasis]]. It was developed by [[AbbVie]], a global biopharmaceutical company, and was approved by the [[Food and Drug Administration|FDA]] in the United States in 2019 under the brand name '''Skyrizi'''. <br />
<br />
== Mechanism of Action ==<br />
Risankizumab works by selectively binding to the p19 subunit of [[interleukin 23]], a [[cytokine]] involved in inflammatory and immune responses. By inhibiting the action of interleukin 23, Risankizumab reduces the inflammation and other symptoms associated with psoriasis.<br />
<br />
== Clinical Trials ==<br />
Risankizumab has undergone several [[clinical trial]]s to evaluate its safety and efficacy. In Phase 3 trials, Risankizumab demonstrated superior efficacy compared to [[Ustekinumab]], another monoclonal antibody used for the treatment of psoriasis.<br />
<br />
== Side Effects ==<br />
Common side effects of Risankizumab include upper respiratory infections, headache, and fatigue. Serious side effects may include severe infections and allergic reactions.<br />
<br />
== Approval ==<br />
Risankizumab was approved by the FDA in April 2019 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It has also been approved in the European Union and other countries.<br />
<br />
== See Also ==<br />
* [[Monoclonal antibodies]]<br />
* [[Psoriasis]]<br />
* [[Interleukin 23]]<br />
* [[Clinical trial]]<br />
* [[Food and Drug Administration]]<br />
<br />
[[Category:Monoclonal antibodies]]<br />
[[Category:Psoriasis]]<br />
[[Category:Drugs]]<br />
{{Medicine-stub}}</div>Prab